MORPHOSYS AG O.N. news, videos and press releases - Page 4
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
- DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
- MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
- DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
- DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
- DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
- MorphoSys AG Reports Outcome of Annual General Meeting 2022
- DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
- DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
- DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
- DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
- Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
- DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
- DGAP-News: MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
- National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
- DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
- Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
- DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
- MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
- DGAP-News: MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
- MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
- MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
- MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
